Drug Profile


Alternative Names: HR-301210; INCSHR1210; SHR1210

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Incyte Corporation; Jiangsu Hengrui Medicine Co.; Nanjing Medical University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Oesophageal cancer
  • Phase II/III Hepatocellular carcinoma
  • Phase II Liver cancer
  • Phase I/II Solid tumours
  • Phase I Breast cancer; Malignant melanoma; Nasopharyngeal cancer

Most Recent Events

  • 20 Jul 2017 Tianjin Medical University Cancer Institute and Hospital and Jiangsu HengRui Medicine initiates enrolment in a clinical trial for oesophageal cancer (Late-stage disease) in China (NCT03222440)
  • 26 Jun 2017 Phase-II clinical trials in Oesophageal cancer (First-line therapy, Neoadjuvant therapy) in China (IV) (NCT03200691)
  • 14 Jun 2017 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late-stage disease, Combination therapy) in China (NCT03182673)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top